Barclays analyst Gena Wang maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price target of $50.00. The company’s shares closed yesterday at $7.00. Easily identify ...

H.C. Wainwright lowered the firm’s price target on Regenxbio (RGNX) to $34 from $36 and keeps a Buy rating on the shares following the Q4 ...

We feel now is a pretty good time to analyse REGENXBIO Inc.'s (NASDAQ:RGNX) business as it appears the company may be on the cusp of a considerable accomplishment. REGENXBIO Inc., a clinical-stage ...

Shares of REGENXBIO stock opened at $8.24 on Thursday. The stock has a market cap of $408.25 million, a PE ratio of -1.64 and a beta of 1.35. The business has a fifty day simple moving average of ...

Patrick Christmas; Executive Vice President, Chief Legal Officer; Regenxbio Inc Curran Simpson; Chief Operating Officer, Executive Vice President; Regenxbio Inc Stephen Pakola; Executive Vice ...

ROCKVILLE, Md. - REGENXBIO Inc. (NASDAQ:RGNX) has shared new interim data from its ongoing Phase I/II AFFINITY DUCHENNE® trial, evaluating RGX-202, an investigational gene therapy for Duchenne ...

REGENXBIO Inc. has a 52-week low of $5.62 and a 52-week high of $23.14. The firm has a market capitalization of $421.13 million, a PE ratio of -1.69 and a beta of 1.35.

Regenxbio (NASDAQ:RGNX) and Solid Biosciences (NASDAQ:SLDB) witnessed contrasting fortunes on Tuesday after Sarepta Therapeutics (NASDAQ:SRPT) disclosed a mortality linked to its gene therapy ...

Regenxbio plans to submit a BLA for RGX-202 in mid-2026, with Phase 3 enrollment ongoing. How to Spot the Market Bottom: Matt Maley has navigated every major market turn in the last 35 years ...

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Regenxbio Inc. (RGNX) on Thursday reported a loss of $51.2 million in its fourth quarter. On a per-share basis, the Rockville, Maryland-based ...

5 analysts have shared their evaluations of Regenxbio RGNX during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings ...